ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 023,32
0,83%
Dow Jones
38 675,68
0,00%
DAX
18 181,34
1,04%
Brent Oil
83,465
0,41%
Bitcoin
63 393,29
-0,95%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Lexaria Bioscience Corporation (LEXX)

  7. Lexaria Bioscience Corporation (LEXX) Actualités

LEXX

Lexaria Bioscience (LEXX)

Lexaria Bioscience Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:LEXX
DateHeureSourceTitreSymboleSociété
06/03/202412h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
01/03/202420h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202421h47Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202412h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202420h20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202418h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
29/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
24/01/202419h33Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LEXXLexaria Bioscience Corporation
18/01/202420h38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEXXLexaria Bioscience Corporation
12/01/202423h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LEXXLexaria Bioscience Corporation
11/01/202414h30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNASDAQ:LEXXLexaria Bioscience Corporation
10/01/202414h45InvestorsHub NewsWireGLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsNASDAQ:LEXXLexaria Bioscience Corporation
09/01/202414h30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformNASDAQ:LEXXLexaria Bioscience Corporation
08/01/202414h45InvestorsHub NewsWireExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsNASDAQ:LEXXLexaria Bioscience Corporation
08/12/202322h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LEXXLexaria Bioscience Corporation
30/11/202322h14Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LEXXLexaria Bioscience Corporation
20/11/202323h16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LEXXLexaria Bioscience Corporation
01/11/202318h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202313h45InvestorsHub NewsWireGet Ready for Next Generation of Diabetes, Weight-Management DrugsNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202313h30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNASDAQ:LEXXLexaria Bioscience Corporation
31/10/202313h31GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsNASDAQ:LEXXLexaria Bioscience Corporation
30/10/202313h45InvestorsHub NewsWireCan Diabetes, Weight-Loss Drugs Get Even Better?NASDAQ:LEXXLexaria Bioscience Corporation
18/09/202316h42Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:LEXXLexaria Bioscience Corporation
09/08/202318h35Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
23/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LEXXLexaria Bioscience Corporation
10/05/202322h31Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:LEXXLexaria Bioscience Corporation
09/05/202312h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LEXXLexaria Bioscience Corporation
28/04/202322h44Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:LEXXLexaria Bioscience Corporation
14/04/202318h45Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LEXXLexaria Bioscience Corporation
22/03/202313h04Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LEXXLexaria Bioscience Corporation
 Showing the most relevant articles for your search:NASDAQ:LEXX

Dernières Valeurs Consultées

EU
GLE
Societe Generale
NASDAQ
AMZN
Amazon.com
FTSE
UKX
FTSE 100
SPI
SP500
S&P 500
EU
BEL20
Bel 20
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
KO
Coca Cola
EU
PX1
CAC 40
EU
RI
Pernod Ricard
EU
DG
Vinci
EU
ACA
Credit Agricole
NYSE
DIS
Walt Disney
EU
HO
Thales
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés